Jazz Pharmaceuticals

A delicate balancing act for Immunogen
A delicate balancing act for Immunogen
EP Vantage
Immunogen
mirvetuximab soravtansin
Jazz Pharmaceuticals
IMGN779
IMGN632
Flag link:
Jazz Pharmaceuticals Hits All the Right Notes in Q1
Jazz Pharmaceuticals Hits All the Right Notes in Q1
Motley Fool
Jazz Pharmaceuticals
earnings
Flag link:
Jazz's narcolepsy treatment passes Phase 3 test
Jazz's narcolepsy treatment passes Phase 3 test
Biopharma Dive
Jazz Pharmaceuticals
narcolepsy
JZP-258
Xyrem
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings
Yahoo/Benzinga
Roche
SAGE Therapeutics
Ligand Pharmaceuticals
brexanolone
Tecentriq
Jazz Pharmaceuticals
JZP-110
Sanofi
Lexicon Pharmaceuticals
Zynquista
PhaseBio
AstraZeneca
Amarin
Leap Therapeutics
Strongbridge
Flag link:
Jazz’s Vyxeos rollout hit a wall in Q3. What’s the holdup?
Jazz’s Vyxeos rollout hit a wall in Q3. What’s the holdup?
Fierce Pharma
Jazz Pharmaceuticals
Vyxeos
Flag link:
Jazz hiring 100-plus sales representatives to prep for new narcolepsy and AML launches
Jazz hiring 100-plus sales representatives to prep for new narcolepsy and AML launches
Fierce Pharma
Jazz Pharmaceuticals
hirings
drug reps
solriamfetol
narcolepsy
Europe
Vyxeos
AML
Flag link:
U.S. court denies Jazz Pharma bid to revive narcolepsy drug patents
U.S. court denies Jazz Pharma bid to revive narcolepsy drug patents
Reuters
Jazz Pharmaceuticals
narcolepsy
Xyrem
Amneal
generics
Flag link:
Kickback Allegation Settlements Pile Up for Pharmaceutical Companies
Kickback Allegation Settlements Pile Up for Pharmaceutical Companies
RAPS.org
kickbacks
Medicare
physicians
Pfizer
Jazz Pharmaceuticals
Valeant Pharmaceuticals
Shire
Omnicare
Flag link:
Sparks sells regulatory fast pass to Jazz for $110M
Sparks sells regulatory fast pass to Jazz for $110M
Biopharma Dive
Spark Therapeutics
Jazz Pharmaceuticals
priority review vouchers
Flag link:
Jazz, ImmunoGen partner on hematology, oncology drug development
Jazz, ImmunoGen partner on hematology, oncology drug development
BioPharma Dive
Jazz Pharmaceuticals
Immunogen
oncology
hematology
drug development
Flag link:
FDA approves Jazz Pharmaceuticals’ liposomal AML chemotherapy
FDA approves Jazz Pharmaceuticals’ liposomal AML chemotherapy
Drug Delivery Business News
FDA
Jazz Pharmaceuticals
liposomal chemotherapy
Vyxeos
AML
Flag link:
Jazz nabs early FDA nod for AML med Vyxeos. Is diversifying M&A next?
Jazz nabs early FDA nod for AML med Vyxeos. Is diversifying M&A next?
Fierce Pharma
Jazz Pharmaceuticals
FDA
AML
Vyxeos
M&A
Flag link:
Rare-Disease Drugmakers Join in Worries Over GOP Health Overhaul
Rare-Disease Drugmakers Join in Worries Over GOP Health Overhaul
Bloomberg
rare disease
healthcare reform
Shire
Jazz Pharmaceuticals
Sanofi
Roche
Biogen
Alexion
Vertex Pharmaceuticals
Flag link:
Upstart women’s oncology company in-licenses PhII PARP; Beijing biotech grabs $29M startup round
Upstart women’s oncology company in-licenses PhII PARP; Beijing biotech grabs $29M startup round
Endpoints
oncology
PARP inhibitors
2X Oncology
Eisai
2X-121
Jazz Pharmaceuticals
Flag link:
3 Reasons Jazz Pharmaceuticals Stock Could Fall
3 Reasons Jazz Pharmaceuticals Stock Could Fall
Motley Fool
Jazz Pharmaceuticals
Vyxeos
Xyrem
Flag link:
Jazz hits a nigh note with positive narcolepsy results
Jazz hits a nigh note with positive narcolepsy results
BioPharma Dive
Jazz Pharmaceuticals
narcolepsy
JZP-110
Flag link:
Jazz Pharmaceuticals stock surges 7% on settlement with Hikma over generic drug
Jazz Pharmaceuticals stock surges 7% on settlement with Hikma over generic drug
Marketwatch
Jazz Pharmaceuticals
Hikma
generics
Xyrem
narcolepsy
Flag link:
Jazz beats 4Q profit forecasts
Jazz beats 4Q profit forecasts
Yahoo/AP
earnings
Jazz Pharmaceuticals
Flag link:
Top 25 rare disease brands, by sales
Top 25 rare disease brands, by sales
Medical Marketing and Media
rare disease
Copaxone
Teva Pharmaceutical
Avonex
Biogen
Sensipar
Soliris
Alexion
Xyrem
Jazz Pharmaceuticals
Flag link:
3 Biotechs Likely to Be Acquired in 2017
3 Biotechs Likely to Be Acquired in 2017
Motley Fool
M&A
Clovis Oncology
Intercept Pharma
Jazz Pharmaceuticals
Flag link:

Pages